Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most vaccine-related statements (live vaccine avoidance/concerns and immune response effects) are aligned with the provided label excerpt, but several claims go beyond the supplied labeling text (e.g., specific 4-week wait recommendation) and there is a mismatch between the provided label excerpts (avoid use) versus the AI response’s timing-based FDA recommendation.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A).
Drug/active ingredient description in prompt: secukinumab is an IL-17A antagonist.
There are concerns that live vaccines may not be safe to administer after Cosentyx because Cosentyx may interfere with the vaccine's ability to stimulate an immune response.
5.7 Immunizations: "COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX."
Cosentyx suppresses the immune system by reducing the production of cytokines.
Not supported by the provided label excerpts. (No cytokine-production mechanism statement is present in the supplied text.)
Cosentyx may potentially reduce the effectiveness of live vaccines.
5.7 Immunizations: "may alter a patient's immune response to live vaccines" supports the concept of altered/possibly reduced vaccine immune response, though the excerpt does not explicitly say "effectiveness."
Unsupported Statements
By blocking IL-17A, Cosentyx reduces inflammation and slows disease progression in patients with autoimmune diseases.
No corresponding indication/mechanistic efficacy statement is provided in the supplied excerpts beyond the general IL-17A antagonist description and the listed indication statements.
Cosentyx can suppress the immune system.
The provided label excerpt says COSENTYX "may increase the risk of infections" and "may alter" immune response to live vaccines, but it does not explicitly state "suppress the immune system."
Cosentyx suppresses the immune system by reducing the production of cytokines.
No cytokine-production reduction mechanism is included in the supplied label excerpts.
Reduced immune response from Cosentyx may make it more difficult for the body to respond to live vaccines.
The label excerpt states COSENTYX "may alter a patient's immune response to live vaccines" but does not describe live vaccine response difficulty in this phrasing.
The FDA recommends that patients taking Cosentyx wait at least 4 weeks before receiving live vaccines.
The supplied label excerpt only states to "Avoid use of live vaccines" in patients treated with COSENTYX and does not provide any 4-week waiting period.
The FDA recommendation about waiting at least 4 weeks before live vaccines after Cosentyx is based on limited data.
No such timing rationale or evidence characterization is present in the supplied label excerpts.
It is essential to consult with a healthcare provider before receiving a live vaccine while taking Cosentyx.
The excerpt provides an avoidance instruction but does not include an explicit "consult" requirement.
The safety of live vaccines after Cosentyx administration is a complex issue that requires careful consideration.
No statement in the provided label excerpts characterizes the issue as "complex" or "requires careful consideration".
Contradictions
Low
AI Statement
The FDA recommends that patients taking Cosentyx wait at least 4 weeks before receiving live vaccines.
Label Reference
5.7 Immunizations: "Avoid use of live vaccines in patients treated with COSENTYX." No 4-week waiting period is stated in the provided label excerpt.
Important Omissions
The label excerpt specifies an instruction to "Avoid use of live vaccines" in patients treated with COSENTYX, without stating a specific waiting interval; the AI response emphasized a 4-week wait that is not in the provided label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI introduces an unsupported specific 4-week timing recommendation for live vaccines. If followed, it could lead to live vaccine administration contrary to the supplied label instruction to avoid live vaccines in patients treated with COSENTYX.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
An unsupported claim specifies a 4-week wait after Cosentyx before live vaccines; the provided label excerpt instead directs to avoid live vaccines in patients treated with COSENTYX and does not mention any waiting period.
Suggested Improvement
Replace the 4-week timing claim with the label-supported statement: COSENTYX may alter immune response to live vaccines and live vaccines should be avoided in patients treated with COSENTYX (as shown in Section 5.7).